The publication of a peer-reviewed study by InMed Pharmaceuticals on the anti-inflammatory effects of cannabinol could positively impact the company's stock. The study supports the therapeutic potential of cannabinol for skin diseases, which may enhance InMed's product offerings and market position. This development is likely to attract investor interest and potentially drive the stock price up in the short term.